References

  1. https://coronavirus.jhu.edu/map.html
  2. Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75. doi: 10.1128/AAC.00339-08. Epub 2009 Feb 2. PubMed PMID: 19188392; PubMed Central PMCID: PMC2663072.
  3. Carmichael SJ, Charles B, Tett SE. Population Pharmacokinetics of Hydroxychloroquine in Patients with Rheumatoid Arthritis. Ther Drug Monit. 2003 Dec;25(6):671-81. PubMed PMID: 14639053.
  4. Morita S, Takahashi T, Yoshida Y, Yokota N. Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus. Ther Drug Monit. 2016;38:259–67.
  5. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point : Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clin Infect Dis. 2020;2:1–25.
  6. Gautret al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrob Agents – In Press 17 March 2020. – DOI: 10.1016/j.ijantimicag.2020.105949
  7. Gautret P, Lagier JP, Parola P et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. (2020)
  8. Chen J, Liu D, Lui L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 COVID-19). Journal of Zhejiang University 2020; 03-03
  9. Zhaowei Chen, Jijia Hu, Zongwei Zhang, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020.03.22.20040758; doi: https://doi.org/10.1101/2020.03.22.20040758)http://kns.cnki.net/kcms/detail/33.1248.R.20200309.1507.006.html
  10. Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N, No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection, Medecine et Maladies Infectieuses (2020), doi: https://doi.org/10.1016/j.medmal.2020.03.006
  11. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
  12. Garcia-Cremades M, Solans BP, Hughes E, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative. Clin Pharmacol Ther 2020 (in press)
  13. Lim et al. Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in hemoprophylaxis against Malaria Caused by Plasmodium vivax. Antimicrob Agents Chemother. Apr 2009; 53 (4): 1468-1475.Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol. 2018 May;30(3):249-255. doi: 10.1097/BOR.0000000000000500. Review. PubMed PMID: 29517495.
  14. Tett SE et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989 Jun;27(6):771-9.
  15. Balevic SJ et al. Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. Clin Pharmacokinet. 2019 Apr;58(4):525-533.
  16. Blanchet B, Moez J, Allard M, le guern vet al. Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/hydroxychloroquine-levels-in-patients-with-systemic-lupus-erythematosus-comparison-of-whole-blood-and-serum-levels/. Accessed April 20, 2020.
  17. Wang F-S, Zhang C. What to do next to control the 2019-nCoV epidemic;Lancet 2020; 395: 391–93
  18. Zheng, Y., Ma, Y., Zhang, J. et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol (2020). https://doi.org/10.1038/s41569-020-0360-5
  19. Wu C-I, Postema PG, Arbelo E, Behr ER, Bezzina CR, Napolitano C, Robyns T, Probst V, Schulze-Bahr E, Remme CA, Wilde AAM, SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes, Heart Rhythm (2020), doi: https://doi.org/10.1016/j.hrthm.2020.03.024.